Morgan Stanley My Md Pharmaceuticals, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.22 - $0.58 $2,386 - $6,290	10,846 New	10,846 $2,000
Q4 2023 Feb 13, 2024	SELL	$0.22 - $0.58 $330 - $869	-1,500 Reduced 12.15%	10,847 $2,000
Q3 2023 Nov 15, 2023	SELL	$0.47 - $1.87 $30,650 - $121,950	-65,214 Reduced 84.08%	12,347 $7,000
Q2 2023 Aug 14, 2023	BUY	$1.44 - $2.26 $57,015 - $89,482	39,594 Added 104.29%	77,561 $116,000
Q1 2023 May 15, 2023	SELL	$1.1 - $2.86 $162,500 - $422,502	-147,728 Reduced 79.55%	37,967 $65,000
Q4 2022 Feb 14, 2023	SELL	$0.92 - $96.0 $91,784 - $9.58 Million	-99,766 Reduced 34.95%	185,695 $213,000
Q3 2022 Nov 14, 2022	SELL	$2.22 - $82.2 $1.18 Million - $43.6 Million	-530,857 Reduced 65.03%	285,461 $745,000
Q2 2022 Oct 27, 2022	SELL	$2.0 - $4.78 $184,516 - $440,993	-92,258 Reduced 10.15%	816,318 $1.77 Million
Q2 2022 Aug 15, 2022	SELL	$2.0 - $4.78 $184,516 - $440,993	-92,258 Reduced 10.15%	816,318 $1.77 Million
Q1 2022 Oct 27, 2022	BUY	$3.34 - $6.05 $308,141 - $558,160	92,258 Added 11.3%	908,576 $4.23 Million
Q1 2022 May 13, 2022	BUY	$3.34 - $6.05 $953,710 - $1.73 Million	285,542 Added 45.83%	908,576 $4.23 Million
Q4 2021 Feb 14, 2022	SELL	$5.46 - $9.69 $246,338 - $437,183	-45,117 Reduced 6.75%	623,034 $3.78 Million
Q3 2021 Nov 15, 2021	BUY	$4.64 - $7.94 $3.1 Million - $5.31 Million	668,151 New	668,151 $4.81 Million

30.2K

Ticker MYMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,470,000
Market Cap $67.5M
Description
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and o...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.